Neil Stahl - EVP Research and Development, Regeneron Pharmaceuticals, Inc
As of December 14, 2021
Neil Stahl Net Worth
- Net worth is estimated to be at least $122.29M
- Owns at least 33,414 units of Regeneron Pharmaceuticals, Inc stock
- Sold an estimated value of $311.04M in the last 18 years at Regeneron Pharmaceuticals, Inc
Neil Stahl Trading
- Largest purchase of shares was 52,500 units , worth over $7.82M on May 18, 2021
- Largest sale of shares was 101,000 units , worth over $56.5M on November 9, 2015
- In total has made about 60 transactions over 18 years
- Usually trades in December, with the busiest year in 2020, 2012 and 2014
Neil Stahl
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
Regeneron Pharmaceuticals, Inc Executive Compensation
Name |
Year
|
Salary
|
Stock Awards
|
Other Earnings Plans or Compensations
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|
| Leonard S. Schleifer, M.D., Ph.D. | 2020 | $1,480,119 | $130,000,032 | $3,567,714 | $3,567,714 | $302,256 | $135,350,121 |
| Leonard S. Schleifer, M.D., Ph.D. | 2019 | $1,377,100 | $4,983,226 | $3,057,162 | $3,057,162 | $338,043 | $21,455,117 |
| Leonard S. Schleifer, M.D., Ph.D. | 2018 | $1,330,500 | - | $2,953,710 | $2,953,710 | $896,432 | $26,520,555 |
| George D. Yancopoulos, M.D., Ph.D. | 2020 | $1,258,096 | $130,000,032 | $3,004,391 | $3,004,391 | $120,800 | $134,383,319 |
| George D. Yancopoulos, M.D., Ph.D. | 2019 | $1,170,500 | $4,983,226 | $2,598,510 | $2,598,510 | $212,313 | $20,664,135 |
| George D. Yancopoulos, M.D., Ph.D. | 2018 | $1,130,900 | - | $2,510,598 | $2,510,598 | $399,718 | $25,381,129 |
| Robert E. Landry | 2020 | $825,577 | $949,560 | $938,872 | $938,872 | $24,195 | $6,197,703 |
| Robert E. Landry | 2019 | $730,000 | $2,840,008 | $811,395 | $811,395 | $23,470 | $7,931,542 |
| Robert E. Landry | 2018 | $680,000 | $4,767,500 | $581,400 | $581,400 | $19,535 | $9,356,619 |
| Daniel P. Van Plew | 2020 | $825,577 | $3,409,560 | $938,872 | $938,872 | $20,945 | $8,654,453 |
| Daniel P. Van Plew | 2019 | $683,100 | $2,840,008 | $759,266 | $759,266 | $20,470 | $7,829,513 |
| Daniel P. Van Plew | 2018 | $660,000 | - | $677,160 | $677,160 | $19,915 | $9,007,222 |
| Andrew J. Murphy, Ph.D. | 2020 | $726,923 | $5,025,288 | $887,250 | $887,250 | $24,195 | $10,998,914 |
| Andrew J. Murphy, Ph.D. | 2019 | $600,000 | $4,702,308 | $666,900 | $666,900 | $23,470 | $9,519,347 |
| No matching records found | |||||||
Source: https://www.sec.gov/Archives/edgar/data/872589/000093041321000869/c101011_def14a.htm
Regeneron Pharmaceuticals, Inc Insider Trading
- The most recent transaction was 10,000 units sold on May 18, 2022 by Andrew Murphy worth over $6.54M
- In the last 19 years, insiders at Regeneron Pharmaceuticals, Inc sold an estimated value of $17.26B and bought an estimated value of $3.4B
- The most active traders are Joseph L Goldstein, Director, Michael S Brown, Director, and P. Roy Vagelos, Director
- Insider trading is most common in December, with the busiest year in 2014
REGENERON PHARMACEUTICALS, INC. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||